Media
Press Releases
Intellomx Announces New AI Technology
CAMBRIDGE, UNITED KINGDOM, April 28, 2025 Intellomx (Intelligent OMICS Ltd) today announced the deployment of Intellomx Pilot, delivering rapid identification of novel drugs arising from its existing precision therapeutic
target identification capability, offering pharmaceutical innovators a powerful tool to streamline and de-risk the drug discovery process.
Intellomx Headlines BioTrinity 2025
Intellomx announces new swarm-based technology for precision target identification and drug docking
(click above for link to PR)
London, UK – 18 April, 2025- Why has AI not delivered on its ambitious promise in drug discovery? This was the provocative opening posed by Professor Graham Ball during the AI Science Spotlight at BioTrinity in London last week—a question that cut to the heart of today’s drug discovery challenges
Intelligent OMICS Ltd in AI Driven research collaboration with Janssen
Intelligent OMICS Ltd announce collaboration to leverage AI for novel target discovery in haematological cancers
(click above for link to PR)
London, UK – 1 September, 2023 - Intelligent OMICS Ltd (Intellomx), a leading biotechnology company that applies artificial intelligence (AI) to accelerate drug discovery, today announced a target discovery collaboration with Janssen Research & Development, LLC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to evaluate novel biological targets for the treatment of haematological cancers. The agreement was facilitated by Johnson & Johnson Innovation.
EIN Presswire 10th August 2023
AI Drug Discovery pioneer Intellomx Joins Johnson & Johnson Innovation – JLABS
(click above for link to PR)
​NOTTINGHAM, UNITED KINGDOM, August 10, 2023 /EINPresswire.com/ -- Intelligent Omics Ltd (Intellomx) is
pleased to announce that it has joined Johnson & Johnson Innovation – JLABS, a premier life science incubator
program.
JLABS provides entrepreneurs with the lab space, resources and support needed to bring breakthrough healthcare solutions to patients around the world.
EIN Presswire 1st March 2022
Grundy joins Intellomx
The Senior Management team at Intelligent OMICS is delighted to report the appointment of industry veteran Dr Robert Grundy to the role of VP Business Development.
Contact: rob.grundy@intellomx.com
​
Click photo for details
Front cover and
pages 10 to 13
OBN CONNECT Magazine Autumn 2021
AI: Vive la Revolution
Article from our CEO Dr Simon Haworth with input from Prof Ball plus leaders at Medicines Discovery Catapult and Arctoris regarding our lung cancer assets and the wider implications of AI application for global drug discovery.
Intellomx PR April 2019
Intellomx Press Release about Artificial Intelligence
This Press Release discusses Intellomx and the emerging world of Artificial Intelligence for drug discovery.
Corporate Presentations
Intellomx Update
Biology 2.0: Combining machine-learning, robotics and biology to deliver drug discovery of tomorrow
This is our latest news on a new collaboration to validate our AI-discovered drug targets
Intellomx Executive Summary
Intellomx in Short
This is a one page Executive Summary of Intellomx. Please click on the image to the left to download!